Clinical Trial

Artificial Intelligence in Mammography Screening in Norway

Study acronym: AIMS Norway
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this randomized controlled trial is to compare the number of breast cancers detected among women who had their screening mammograms interpreted by artificial intelligence (AI) in combination with one or two breast radiologists to the number of breast cancers detected after standard independent double reading in BreastScreen Norway. The aims of the study is to prove that screening interpretation with AI in combination with one or two radiologists (the intervention) is non-inferior to standard interpretation procedure.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-04; most recent amendment 2026-01-12.
Status change: Not Yet Recruiting → Recruiting 2024-12-03
Trial Details
NCT Number NCT06032390
Lead Sponsor Norwegian Institute of Public Health
Collaborators: Helse Vest, Helse Midt-Norge, Helse Nord, Norwegian Cancer Society
Conditions Breast Cancer
Enrollment 150,000 participants
Start Date 2024-11-25
Primary Completion 2026-11 (estimated)
Study Completion 2033-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-14